Compare Crocs, Inc. (CROX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Crocs, Inc. trades at $114.86 (market cap $5.60B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Crocs, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CROX | XBI | |
|---|---|---|
Market Cap | $5.60B | $10.11B |
Volume | 1,026,773 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $141.19 | $169.55 |
52-Week Low | $73.39 | $104.99 |
Typical Hold Time | 96 Days | 38 Days |
Enterprise Value | $7.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $114.98, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.55, beating expectations by $0.20, but faces challenges with a negative net income of -$81.20M for 2025. Valuation metrics remain attractive with a P/E of 10.37 and P/S of 1.48, while analyst consensus leans bullish with a $136.78 price target representing 19% upside potential.
CROX presents a mixed investment case with compelling valuation and strong brand positioning offset by recent profitability concerns. The key opportunity lies in the company's product innovation and HEYDUDE brand reset, while risks include consumer spending volatility and execution challenges. With 51% of analysts maintaining buy ratings, the stock offers potential upside if management can restore consistent profitability growth.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
